FDA's Evolving AI/ML Framework: What Device Makers Need to Know

The FDA's finalized guidance on Predetermined Change Control Plans marks a decisive shift in how the agency intends to regulate adaptive AI and machine learning algorithms embedded in medical devices. Under the original framework established in the 2019 action plan, manufacturers were expected to seek a new 510(k) or PMA supplement whenever a software modification could significantly affect safety or effectiveness. The PCCP pathway replaces much of that reactive cycle with a prospective, pre-negotiated contract between the manufacturer and the FDA — one that specifies exactly which modifications are permitted, under what conditions, and how performance monitoring must be conducted.

The practical implications are significant. A manufacturer that embeds a diagnostic algorithm in an imaging device can now define an anticipated performance envelope — for example, a permitted shift in sensitivity/specificity within defined bounds across specific patient populations — and obtain FDA agreement to iterate within that envelope without filing a new submission for each software version. The burden shifts from post-change regulatory paperwork to rigorous pre-change planning and algorithm change protocol documentation. Manufacturers must demonstrate not only what will change, but how change will be detected, measured, and constrained.

Our signal data shows a 340% year-over-year increase in FDA communications referencing PCCP since the final guidance dropped in late 2025. Early adopters are predominantly large imaging OEMs and clinical decision support software developers, but mid-market companies are now filing PCCP-inclusive submissions at an accelerating rate. The FDA's Digital Health Center of Excellence has also indicated it will publish worked examples covering cardiovascular AI and radiology AI use cases in mid-2026, which should lower the barrier for less-experienced filers.

The strategic takeaway for device makers is that PCCP is not simply a regulatory shortcut — it is a change management discipline that must be embedded in product development from inception. Teams that invest now in algorithm change protocols, performance monitoring architectures, and cross-functional PCCP review processes will be positioned to compress iteration cycles and capture first-mover advantages in AI-enabled diagnostics. Those who treat PCCP as a post-development compliance exercise will find the documentation burden considerable and the FDA's expectation for algorithmic transparency difficult to meet retroactively.